ProMetic Life Sciences Inc. (PLI) 2017年年度报告「TSX」.pdf

1、Annual Report 2017ContentsHistory.1Message to Shareholders .4MD&A.9Financial statements.52Prometic Life Sciences Inc.History1Prometic,a Pharmaceutical Company specialised in Rare and Orphan DiseasesACL/Spin offU of Cambridge(1988)IPO Toronto Stock Exchange(1998)IVIG(Immunoglobulins)Interalpha inhibi

2、tor proteinsAlpha 1 antitrypsinFibrinogenAuto-Immune/OncologyPBI-1737PBI-1393(BioChem in-licensing)Hematology/FibrosisPBI-1402(Innovon in-licensing)FibrosisPBI-4050PBI-4547PBI-4425Affinity Chromatographyenabling the extraction/purification(18 Products approved by FDA/EMAwith Prometic technology in t

3、heir DMF)Small Molecules Discovery platform(R&D Montreal&Cambridge UK)Plasma-Derived Platform(PPPS)(R&D Rockville USA&Montreal)IVIGPBI-4050-Ph3 IPF-Ph2/3 AlstrmWound healingPBI-4547PBI-4425Plasminogen ScShire acquires BioChem&close R&D(2000)Scientists join Prometic(20012006)2 joint venturesPrometic

4、Corporate HistoryFrom enabling the manufacturing of biopharmaceuticals to developing its own drug pipeline.Better known up until a few years ago for its bioseparation and enabling of manufacturing of biopharmaceuticals expertise,Prometic has during 2017,continued its transition that has transformed

5、the company into a biopharmaceutical corporation with two drug discovery platforms focusing on rare and orphan diseases representing significant and unmet medical needs.Prometic Life Sciences Inc.2The first platform stems from the discovery of two receptors the regulation of which is at the core of

6、how we heal:tissue regeneration and scar resolution as opposed to fibrosis.One of the lead drug candidates emerging from this platform,PBI-4050,is entering pivotal phase 3 clinical trials for the treatment of IPF(Idiopathic Pulmonary Fibrosis).The second drug development platform leverages Prometics